¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º faMUd#o&  
XP{ nf9&  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ ;7 IVg[f  
EH,uX{`e  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) J^t=.-a|  
c/g(=F__[  
1. ICAM-1 S3 x:]E:   
_@"Y3L qi  
2. interleukin 12(IL-12) Z;%qpsq  
~t#'X8.)  
3. tumor infiltrating lymphocyte V8,$<1Fi;-  
RmzK?muk  
4. TCR/CD3 complex 5d L-v&W  
]B5\S  
5. hematopoietin receptor family kxf'_Nzy  
E6@+w.VVO  
6. individual idiotype(IdI) N%Lh_2EzqV  
(tVY /(~#  
7. integrin [n< U>up  
xt3IR0  
8. colony-stimulatory factor (CSF) $*2uI?87}:  
Ebq5P$  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© OZISh?  
g@1MIm c'!  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? 9Y/c<gbY  
sL!6-[N  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ 1p{\jCi, 2  
<:%Iq13D  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ!\!fd(BN  
@A yC0}  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ vn kktD'n  
=-vk}O0C  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) #s]]\  
NIYAcLa@n8  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ <89 js87  
=Qz 8"rt#  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) 0TVO'$Gvi  
bu$5gGWVf  
3. immunoglobulin superfamily (IgSF) i5)trSM|  
!>2s5^JI9  
4. selectin 1`h`-dqr#  
"b} ^ xy  
5. anti-idiotypic antibody (¦ÁId) hL8QA!  
Nzr zLK  
6. major histocompatibility complex(MHC) os#j;C]l  
?EYF61? rw  
7. immunotolerance u2!8'-Ai  
Nf$Y -v?i  
8. biological reponse modifier(BRM) ;((gmg7,  
43 |zjE  
9. immune reponse gene (Ir gene) Kj'm<]u  
e[{LNM{/#  
10. reshaped antibody (or reconstituted antibody) J.El&Dev  
hDz_BvE  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© _c%~\LOk  
y0rT=kU  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ ;9;.!4g/T  
E!ZDqq  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? ;r`[6[AG  
nY(jN D  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ OlV>zam  
TmO\!`  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? Z1q '4h=F.  
E9 q8tE}  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ lOZ.{0{f,  
9]hc{\  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? ,`H=%#  
N}s[0s  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ M*0&3Y Z  
^hZwm8G  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ Tk+\Biq   
7E|0'PPR  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? (|bht0  
o#w6]Fmc  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 6G1Z"9<2*  
B?TA S  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: l`,`N+FG  
O|av(F9  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: x6F\|nb  
HlV3rYh  
ÃâÒßѧ VX;u54hS  
o@ ;w!'  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© V+D "_  
H&%=>hyX  
1. CD8 TcRnjsY$  
~ |!q>z  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) c~c3;  
/:%^Vh3XF  
3. immunoglobulin fold(Ig fold) R %}k52`  
hvpn=0@ M  
4. cadherin (Ca-dependent cell adhesion moleculers) P.[>x  
MTqbQ69v  
5. idiotype-anti-idiotypic antibody immune network theory c&R .  
|y=CmNG,  
6. HLA class II antigen vTB*J,6.  
-j<UhW  
7. complementarity-determining region (CDR) \HH|{   
J qU%$[w  
8. perforin(or pore-forming protein ,PFP) .h*&$c/l  
=z@'vu$Fh  
9. high affinity IL-2 receptor Jl^oDW  
j^64:3  
10. artificial active immunization _$Fi]l!f  
o}Xp-P   
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© =%RDT9T.  
zV2c `he%z  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠFyY;F;4P  
wOa_"  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 6 a$%  
cBm3|@7  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ |E?%Cj^W  
Mz"kaO  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ W C`1;(#G  
j5 ui  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ :A 1,3g  
_wX'u,HrC  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? I #A`fJ  
b,K1EEJ  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ O&X-)g=  
&7<~Q\XZbI  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ "Dy&`  
wr#+q1 v  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ :Mt/6}  
?9PNCd3$d  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ oYqC"g&4Z  
}Rf } iG  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© s ^}V  
Rdv"Aj:   
1. immunoglobulin gene rearrangement 4H " *.l  
XBeHyQp  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) |0 Zj/1<$  
R'80{  
3. flow cytometry(FCM) H?B.Hp|  
A&t}s #3  
4. carrier effect {`}RYfZ  
?s _q|d_  
5. positive selection of T lymphocytes in thymus koi e  
.II'W3Fr  
6. mouse TH1(Th1) and TH2(Th2) subsets 2s(K4~ee  
#:{u1sq;  
7. perforin (pore-forming protein ,PFP) L Xx 3  
8>epKFEg  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) D)!k  
2xjS;lpw  
9. SH-2(src-homology region 2) `bxgg'V  
:`uo]B"  
10. Ab2¦Â (internal image) >uUbWKn3  
f^]2qoN  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© yC _X@o-n  
*F9uv)[kz  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹?  k/t4  
$U6)km4  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? +-{H T+W  
t[DXG2&  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ=6%0pu]0  
\dCdyl6V  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ +^%F8GB  
uH7u4f1Q  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠCx@,J\rsQ  
 %RJW@~!  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) ~+|p.(I  
Sx pl%  
ÃâÒßѧרҵ£º 3<'n>'  
uL1 -@D,  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ rv\<Q-uQ8  
le1'r>E$  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? gsZCWT  
=*I>MgCJ  
´«È¾²¡Ñ§×¨Òµ£º 0lW}l9}'-  
V%3K")  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ ni3^J5XW  
o05) I2  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ 7?F0~[eGG  
44cyD _(  
Ïû»¯×¨Òµ£º 92S<TAdPP  
xro  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ F|Ou5WD  
F9Mv$ g79  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? sl`\g1<{`  
!K3 #4   
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ ;K`qSX;;c(  
MQLa+I,S4  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© (L q^C=  
02bv0  
1. Fas(CD95)/FasL R5|c4v{B  
z0doL b^!  
2. common chain of cytokine receptor }oloMtp $  
\V}?K0#bt  
3 . TCR/CD3 complex PT|t6V"wd  
Pij*?qmeQ  
4. negaive selection of thymocytes U^:+J-z{  
D1#fy=u69|  
5. artificial active immune vz/.*u  
^jqQG+`?  
6. anti-idiotypic qfx=   
]qvrpI!E!  
7. IgSF \"|E8A6/  
c|IH|y  
8. Integrin gT?:zd=;  
e@w-4G(;  
9. chemokine 2E;UHR  
Hq ]f$Q6:  
10. B7/CD28 MZl6 J  
^FIpkhw  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© [x{'NwP?  
 MV'q_{J  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ *@^9 ]$*$  
:G!i]1x<  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ 8{^zXJi]m  
~M _ @_  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ `O/1aW1  
PFq1Zai}n|  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ qT5q3A(8  
k[#<=G_=/E  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ lkl+o&D9  
n W:P"L  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ "MM)AY*b  
(#KSwWo{ed  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© z_nv|5"  
y=.`:EB9b  
1. B7/CD28 v,, .2UR4  
t} 6QU  
2. Th1 subset nM#/uuRl|  
:O)\+s-  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© @-zL"%%dw'  
Mj!\EUn  
4. antibody affinity maturation Y2$wL9">  
S,0h &A9  
5. AP-1 W2>VgMR [  
b,h@.s  
6. single chain variable fragment£¨ScFv£© (sDZ&R  
@3*S:;x  
7. NK cell receptor {3Y R_^>?  
8f`r!/j  
8. Zinkernagel-Doherty phenomenon zy'e|92aO  
+,c]FAx4  
9. Ig fold Dbl3ef  
"50 c<sZSB  
10. CD40/CD40L zu_bno!  
GHWt3K:*w  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© um,G^R   
7?@ -|{  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ &v)/mc7D  
:lU#Dm]  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ =|LB,REN  
`c)[aP{vN  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ Xk] uXx:TN  
+v+Dkyf:V  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ VX:Kq<XwQ  
>PYc57S1c  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ lJ Jn@A  
J?Bj=b  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ H0\' ,X  
 CH$K_\  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ 7Y.mp9,  
1\aV4T  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© ]T=o>%  
zeshM8=  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© nx Jx 8d"  
~^/BAc  
1.Co-stimulators (or co-stimulating molecules) GdM|?u&s"  
*P\OP'o_  
2.NK-kB *+%$OH,  
*7{{z%5Pu  
3.Immunoglobulin superfamily rRX F@  
O[8wF86R  
4.antigen-presenting cell (APC) qzWnl[3  
^7Ebg5<  
5.death domain p'kB1)~|  
S;SI#Vg@  
6.CCR and CXCR ~H4Tr[8a  
zG7y$\A  
7.Lectin (or mitogen) '#Q\p6G&_  
^YB3$:@$U  
8.Clusters of differentiation, CD)  [33=+C a  
Z*Fn2I4  
9.B7 family CN6b 982&  
L2%npps  
10.Cytotoxic T lymphocyte, CTL) m[%P3  
!]MGIh#u  
11.IL-15 and IL-15 receptor (IL-15R) t; @T~%  
7Q|v5@;pU  
12.MHC restriction dW %;Z  
NkxW*w%}l  
13.Affinity-chromatography D.YT u$T  
rW2l+:@c  
14.Cyctosprin A, CsA 960rbxKy3  
Gu%}B@4^  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) vl5r~F  
`7_s@4:  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© Bz6Zy)&sAL  
^oZD44$  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 nn/_>%Y  
74a>}+"  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ SI;SnF'[7  
!}Ty "p`  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ M9wj };vy  
%|3NCyJ*7  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© -;t]e6[  
J,^eq@(  
ÃâÒßѧרҵ£º <9Pf] G=  
%I;iP|/  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ M-NY&@Nj  
B#(2,j7M  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ -_~T;cj6  
-W XZOdUjs  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ T\o!^|8  
W\<p`xHk  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) 9h 0^_|"  
} T1~fa  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) " K-2y ^Dl  
oj~0zJI  
1. ADCC(antibody dependent cell-mediated cytotoxicity) F#$[jh$  
Gv zw=~8  
2. »·æß¾úËØ(cyclosporin) }mSfg  
0YVkq?1x9  
3. KIR(killer cell inhibitory receptor) IMay`us]:8  
ok7yFm1\  
4. HLDA(human leucocyte differentiation antigen) VC@{cVT  
P(&9S`I  
5. Interleukin 18(IL-18) !{L`Zd;C>w  
E>3fk  
6. ÕûºÏËØ(integrin) C) "|sG  
?4i:$.A Y  
7. Fas/FasL 'Nbae-pf  
aD:vNX  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) +aWI"d--h  
-5 YvtL  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) >-{)wk;1&  
xW;-=Q  
10. Th1/Th2 ?E?dg#yk  
Zom7y I  
11. »ùÒòÒßÃç(DNAÒßÃç) JS<4%@  
zi*2> 5g  
12. chemokines and chemokine receptor L27i_4E,  
'e4  ;,m  
13. ÃâÒßÄÍÊÜ =-c"~ 4  
D$RQD{*  
14. ¹²´Ì¼¤·Ö×Ó K~_[[)14b  
,afh]#  
15. ËÀÍö½á¹¹Óò(death domain) rI5)w_E?  
F-k3F80=  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) VR/>V7*7@  
KbY5 qou  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? Cr,UP8MO  
XQu~/{A=  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ3+;}2x0-F  
T3o}%wGW  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î $e;_N4d^  
aZYa<28?L%  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ X$zlR) Re  
bGvALz'  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå $up.< qzj  
1.0S>+^JE  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ }Lx?RU+@=  
Ctxs]S tU%  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) kmM1)- v  
_yyQ^M/  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ e g#.f`  
8? 4j-  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ aD,sx#g0  
5tg  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»